Meet the Genezen Team

We are here to help you take your viral vector where it needs to go.

Scroll Down

Meet the team

Specialist expertise in the gene and cell therapy space

Our team boasts a wealth of experience, from academia to long-established CDMO experts. Our team is on hand to support you throughout your journey to therapy, we understand your needs and are driven to help you bring your products to patients. Learn more about our experience, what brings us to Genezen and what motivates us every day.

Management

Steve Favaloro

President and Chief Executive Officer
Read bio

Pratima Cherukuri

Chief Scientific Officer
Read bio

Dave Wilhite

EVP, Alliance Management
Read bio

Brok Weichbrodt

VP of Operations
Read bio

Natasha Rivas

Vice President of Quality and Regulatory
Read bio

Linnie Chang

Vice President of Finance
Read bio

Jill Mullens

Director of Human Resources
Read bio

Board of Directors

Steve Favaloro

President and Chief Executive Officer
Read bio

Bill Vincent

Founder & Executive Chairman
Read bio

David Anderson

Board Member
Read bio

Iain Baird

Board Member
Read bio

Tedd Green

Board Member
Read bio

Diana Caldwell

Board Member
Read bio

Scientific Advisory Board

Kai Lipinski

Scientific Advisory Board Member
Read bio

Chris Ballas

Scientific Advisory Board Member
Read bio

Spencer Hoover

Scientific Advisory Board Member
Read bio

See how we got here

Evolution

Founded in 2014 by current Chairman Bill Vincent, our history is packed with innovation and ambition. Following investment by Ampersand Capital Partners’ in 2021, Genezen is catapulted forward built on a foundation of expansive knowledge in lentiviral and retroviral vector.

Take a look at Genezen's history

Our mission & vision

We collaborate with our clients to connect good science with better cures. With superior service and technical expertise, we develop and manufacture cell and gene therapy products of the highest quality.

Read our full mission statement

See our vacancies

Join the team

We want our employees to be innovative, collaborative problem solvers who are dedicated to meeting the challenges of our clients and a fast-growing market.

Latest insights

LVV Approaches to Pseudotyping and Plasmid…

As cell and gene therapies continue to provide unprecedented advancements in...

Read more

Genezen Announces the Appointment of Steven…

BOSTON, MA and FISHERS, IN. – March 13, 2023 – Genezen,...

Read more

Omar Lamm on Developments in Pharma…

An interview with Omar Lamm discussing his career in pharma, where...

Read more